We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Affymax to Push Hematide NDA Despite J&J Patent Decision
Affymax to Push Hematide NDA Despite J&J Patent Decision
October 8, 2010
An arbitration panel has ruled that Affymax and Johnson & Johnson (J&J) must share several patents related to erythropoietin-stimulating agents (ESAs), and given J&J full control over another, but Affymax says the decision will have no impact on its plans to file for approval of its anemia candidate Hematide.